PRESS RELEASES

INNOLFACT 2.0: Combining Artificial Intelligence and Drug Repositioning in Olfactory Precision Medicine

 

Pamplona, 15/12/2023

 

The R&D strategic project 2023 financed by Navarra Government, INNOLFACT 2.0 (file: 0011-1411-2023-000067) ,aims to develop innovations in the early diagnosis and classification of patients belonging to the Geriatrics and Neurology Services, as well as the development of new therapies that modulate the immune system at the brain level to improve cognitive and motor functions. Specifically, it aims to advance the early diagnosis of neurodegenerative diseases, identify biomarkers indicating disease progression, enable sensory training, and develop intranasal therapies targeted at the central nervous system. This approach consolidates and implements Olfactory Precision Medicine in Navarra.

 

Multidisciplinary Consortium

The INNOLFACT 2.0 project is led by Enrique Santamaría, principal investigator and PI of the Clinical Neuroproteomics Unit of Navarrabiomed, and by Ana María García-Osta, Co-PI of the project and Researcher of the Gene Therapy Program for Neurological Diseases at Cima Universidad de Navarra. The project features a high-level team composed of multidisciplinary profiles in clinical R&D from the University Hospital of Navarra and the University of Navarra's Clinic, as well as from the research centers Navarrabiomed and Cima and the University of Navarra. Eversens will collaborate in identifying biomarkers that correlate with different stages of cognitive decline in patients, for which it will develop medical devices enabling non-invasive monitoring. Meanwhile, NNBi will promote the development of predictive algorithms and digitization in the healthcare environment, thus improving the diagnostic and monitoring capacity of neurodegenerative diseases and aging. The project consortium is completed with the participation of ADItech, coordinator of SINAI, leading the aspect of "Research with a gender dimension" to contribute to the scientific excellence of R&D agents and position Navarra at the international forefront.

 

 

DIAMANTE

 

Pamplona, 14/12/2023

 

The objective of the 2023 R&D Strategic DIAMANTE project, financed by the Government of Navarra (file: 0011-1411-2023-000070), is to improve the effectiveness and accessibility of CAR-T cell-based immunotherapy strategies for people with cancer. To achieve this, this project combines artificial intelligence, state-of-the-art massive sequencing technologies, and advanced gene editing technologies in order to comprehensively understand the biological processes that occur during CAR-T therapies and identify vulnerabilities that can be modulated to enhance their effectiveness. Additionally, through innovative developments and new delivery systems based on non-viral technologies and nanoparticles, the DIAMANTE project will contribute to developing new CAR-T drugs with lower toxicity and greater efficacy, increasing their accessibility by reducing production costs.

 

Multidisciplinary Consortium

The DIAMANTE project is led by Dr. Felipe Prósper from the Hematology Service at the University Clinic of Navarra (CUN). On the other hand, Dr. María Blanco from the University of Navarra (UNAV) leads the group in Nanotechnology applied to pharmaceutical and biomedical materials of interest.

From the Foundation for Applied Medical Research (FIMA), through its Center for Applied Medical Research (CIMA University of Navarra), the following participate: (i) the Computational Biology Program, led by Dr. Mikel Hernáez; (ii) the Hemato-Oncology Program, led by Dr. Juan R. Rodríguez-Madoz; (iii) the Immunology and Immunotherapy Program, led by Dr. Juan Jose Lasarte; and (iv) the Molecular Therapies Program, led by Dr. Antonio Pineda.

From the University Hospital of Navarra (HUN), the Hematology Service, led by Dr. Margarita Redondo, and the Oncology Service, led by Dr. Ruth Vera, participate.

The Miguel Servet Foundation and its center Navarrabiomed (FMS-NB) participate through the Translational Medical Oncology Research Unit.

EVERSENS S.L. specializes in the research, design, and development of biomarker analyzers in exhaled air, and is also a manufacturer and marketer of them. Eversens has extensive experience in R&D projects, developing several projects funded by both the European Union and the Government of Navarra and the European Regional Development Fund.

The company 3P Biopharmaceuticals (3P) specializes in process development and cGMP production of biological drugs using expression systems in bacteria and mammalian cells.

The public company NASERTIC is one of the reference centers for genomic sequencing within the national IMPaCT Strategic Program.

 

 

 

Eversens Exhibits at the 56th SEPAR Congress

 

This Spanish-speaking reference congress allows the Navarrese start-up to present its advancements in the management of asthmatic patients.

 

Granada, 10/06/2023

 

Eversens SL, a start-up based in Pamplona and emerged as a spin-off from the Public University of Navarra (UPNA), has been present at the 56th Congress of the Spanish Society of Pneumology and Thoracic Surgery (SEPAR). During the event, held at the Granada Congress Palace on June 8th, 9th, and 10th, they presented the evernoa device, a fractional exhaled nitric oxide (FeNO) meter used in clinical practice for the diagnosis and monitoring of inflammatory respiratory diseases such as asthma.

 

This congress brought together more than 2000 congressmen, including world-renowned experts in the field of pneumology, making it the reference congress for Spanish speakers for the presentation of scientific and technological advances. During the congress, representatives of Eversens SL had the opportunity to attend various scientific lectures organized by SEPAR. These sessions were of great interest and were enriching for the company's team, as they could closely learn about the latest advancements, research, and therapeutic approaches in asthma management.

 

One of the highlights of Eversens SL's participation in this congress was the exhibition of its FeNO measuring device, evernoa. This device is the only FeNO meter designed and manufactured in Spain and was available at the eversens booth for all congress attendees to try. This allowed healthcare professionals to obtain detailed information about the technical characteristics of the device and the benefits of its use in asthma diagnosis and management.

 

Furthermore, the delegates of this start-up had the opportunity to interact with different medical professionals and experts in the field of pneumology who approached the booth, showing great interest in the evernoa device and recognizing its potential to improve the diagnosis and monitoring of asthmatic patients. These interactions strengthened Eversens SL's network of contacts and laid the groundwork for possible future collaborations in the various research lines that the company has open, as well as for the potential development of innovative solutions to meet the unmet needs in the management of asthmatic patients.

Eversens SL's participation in the SEPAR Congress was a testament to its commitment to innovation and its contribution to the field of respiratory medicine. The company continues to focus on the development and improvement of its products and services to meet the changing needs of medical professionals and patients with respiratory diseases.

 

 

 

Eversens participates in Arab Health, one of the largest medical sector fairs

 

Arab Health, the leading medical technology fair in the Middle East, allows the Navarrese company to present its advances in the care of asthmatic patients to the main players in the sector.

 

Dubai, 25/01/2022

 

Around 30,000 people gather at the largest medical sector fair in the Middle East. Eversens SL, a company specialized in developing innovative solutions in breath analysis, presents its line of evernoa products, which aim to improve patient health by assisting medical professionals in the diagnosis and monitoring of respiratory diseases such as asthma.

Eversens, a spin-off of the Public University of Navarra, has been selected by the European Innovation Council (EIC), along with 17 other European companies, to participate in Arab Health through the Overseas Trade Fair 2.0 program. The program supports EIC beneficiaries in promoting their marketing strategy in foreign markets and seizing business opportunities at trade fairs in the most popular markets, strengthening the EU's innovation brand worldwide.

 

The company launched its first device for exhaled nitric oxide fraction analysis, a biomarker of lung inflammation, in 2019, which assists doctors in the asthma diagnostic process. Since then, over 20,000 tests have been conducted in different national and international hospitals. With this fair, Eversens seeks new collaborations to facilitate access to new markets.

 

Fair Details

More than 3,500 exhibitors from over 60 locations gather from January 24th to 27th at the Dubai World Trade Centre. This fair brings together the world of healthcare, allowing connections, sharing experiences, and doing business.